Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 14/20 | 0.53 |
| ▸ | INSR | P06213 | 10/20 | 0.53 |
| ▸ | IGF1R | P08069 | 8/20 | 0.53 |
| ▸ | EGFR | P00533 | 7/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | ROS1 | P08922 | 1/20 | 0.45 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25871927 | 0.93 | ALK (0.62) | ALKINSRIGF1REGFRMET | |
| SCHEMBL25871978 | 0.91 | ALK (0.60) | ALKINSRIGF1REGFRMET | |
| SCHEMBL25872665 | 0.91 | ALK (0.51) | ALKINSRIGF1REGFRMET | |
| SCHEMBL26495771 | 0.90 | EGFR (0.59) | ALKINSRIGF1REGFRMET | |
| Hydrochloric Acid SCHEMBL25306088 | 0.89 | EGFR (0.58) | ALKINSRIGF1REGFRMET | |
| SCHEMBL25872592 | 0.88 | ALK (0.49) | ALKINSRIGF1REGFRMET | |
| SCHEMBL25872593 | 0.88 | ALK (0.51) | ALKINSRIGF1REGFRMET | |
| SCHEMBL25872787 | 0.86 | MAPK9 (0.51) | ALKINSRIGF1REGFR | |
| SCHEMBL25872052 | 0.85 | ALK (0.62) | ALKINSRIGF1REGFRMET | |
| SCHEMBL25871925 | 0.85 | ALK (0.59) | ALKINSRIGF1REGFRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4212522-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H Biotech Inc. (KR) | 2023-07-19 | — | — | EP | disclosed |